Hypothalamic Physiology and Receptor Signaling — Questions

Drug Classification · Questions 1–6

Identify the pharmacological class or categorical label for each drug. Vocabulary preparation is sufficient to answer every question in this section.

Question 1

Which of the following drugs is classified as a gonadotropin-releasing hormone agonist analog?

A)Degarelix
B)Leuprolide
C)Octreotide
D)Bromocriptine

Correct Answer

B) Leuprolide

Rationale

Leuprolide is a synthetic gonadotropin-releasing hormone agonist analog in which D-amino acid substitution at position 6 and C-terminal amidation confer resistance to peptidase degradation and prolonged receptor occupancy. Degarelix is a gonadotropin-releasing hormone antagonist. Octreotide is a somatostatin analog. Bromocriptine is a dopamine agonist.

Question 2

Which of the following drugs is classified as a somatostatin receptor subtype 2 and subtype 5-selective analog?

A)Octreotide
B)Pasireotide
C)Leuprolide
D)Cabergoline

Correct Answer

A) Octreotide

Rationale

Octreotide is a cyclic octapeptide somatostatin analog with high selectivity for somatostatin receptor subtypes 2 and 5. Pasireotide is a pan-somatostatin receptor agonist with activity at subtypes 1, 2, 3, and 5. Leuprolide is a gonadotropin-releasing hormone agonist analog. Cabergoline is a dopamine agonist.

Question 3

Which of the following drugs is classified as an oral non-peptide gonadotropin-releasing hormone receptor antagonist?

A)Leuprolide
B)Goserelin
C)Elagolix
D)Octreotide

Correct Answer

C) Elagolix

Rationale

Elagolix is a non-peptide small molecule that competitively antagonizes the gonadotropin-releasing hormone receptor with oral bioavailability of approximately 57%. Unlike peptide gonadotropin-releasing hormone analogs, its non-peptide backbone avoids gastrointestinal degradation. Leuprolide and goserelin are peptide gonadotropin-releasing hormone agonist analogs administered by injection or implant. Octreotide is a somatostatin analog.

Question 4

Which of the following antipsychotic drugs is classified as a partial dopamine type 2 receptor agonist?

A)Haloperidol
B)Risperidone
C)Quetiapine
D)Aripiprazole

Correct Answer

D) Aripiprazole

Rationale

Aripiprazole is a partial dopamine type 2 receptor agonist. At pituitary lactotroph cells, its partial agonist activity provides enough dopaminergic tone to suppress prolactin secretion, making it prolactin-sparing. Haloperidol and risperidone are full dopamine type 2 receptor antagonists that reliably elevate prolactin. Quetiapine is a dopamine type 2 receptor antagonist with very low pituitary receptor affinity and is considered prolactin-sparing by a different mechanism.

Question 5

Which of the following drugs is classified as a dopamine type 2 receptor antagonist antipsychotic associated with clinically significant prolactin elevation?

A)Risperidone
B)Aripiprazole
C)Bromocriptine
D)Cabergoline

Correct Answer

A) Risperidone

Rationale

Risperidone is a second-generation antipsychotic that is a potent dopamine type 2 receptor antagonist and is among the antipsychotics most strongly associated with hyperprolactinemia. Aripiprazole is a partial dopamine type 2 receptor agonist and is prolactin-sparing. Bromocriptine and cabergoline are dopamine agonists used to lower prolactin, not raise it.

Question 6

Which of the following drugs is classified as a dopamine agonist used to suppress prolactin secretion?

A)Risperidone
B)Haloperidol
C)Bromocriptine
D)Octreotide

Correct Answer

C) Bromocriptine

Rationale

Bromocriptine is an ergot-derived dopamine agonist that activates dopamine type 2 receptors on pituitary lactotroph cells, suppressing prolactin secretion. It is used for prolactinoma and other hyperprolactinemic states. Risperidone and haloperidol are dopamine type 2 receptor antagonists that elevate prolactin. Octreotide is a somatostatin analog with no direct action at dopamine receptors.

Core Pharmacology · Questions 7–14

Apply your understanding of drug mechanisms, receptor coupling, and pharmacokinetics. Each question requires one reasoning step.

Question 7

The gonadotropin-releasing hormone receptor is coupled to a Gq protein. Which of the following second messengers is generated by the downstream activation of phospholipase C beta at this receptor?

A)Cyclic adenosine monophosphate
B)Diacylglycerol only
C)Inositol trisphosphate and diacylglycerol
D)Cyclic guanosine monophosphate

Correct Answer

C) Inositol trisphosphate and diacylglycerol

Rationale

Gq protein activation stimulates phospholipase C beta, which cleaves phosphatidylinositol 4,5-bisphosphate into two second messengers: inositol trisphosphate and diacylglycerol. Inositol trisphosphate mobilizes calcium from the endoplasmic reticulum and diacylglycerol activates protein kinase C, together driving luteinizing hormone and follicle-stimulating hormone exocytosis. Cyclic adenosine monophosphate is generated by Gs-coupled receptors via adenylyl cyclase. Cyclic guanosine monophosphate is produced by guanylyl cyclase activation, not by Gq signaling.

Question 8

A patient taking a dopamine type 2 receptor antagonist for nausea develops galactorrhea. Which of the following best explains the mechanism of prolactin elevation in this patient?

A)Blockade of dopamine type 2 receptors on pituitary lactotroph cells removes the tonic inhibitory signal that normally suppresses prolactin secretion
B)Stimulation of dopamine type 2 receptors on hypothalamic neurons increases tuberoinfundibular dopaminergic neuron firing
C)Inhibition of prolactin receptor internalization prolongs prolactin signaling at target tissues
D)Blockade of somatostatin receptors on lactotroph cells removes inhibitory tone on prolactin gene transcription

Correct Answer

A) Blockade of dopamine type 2 receptors on pituitary lactotroph cells removes the tonic inhibitory signal that normally suppresses prolactin secretion

Rationale

Dopamine released from tuberoinfundibular dopaminergic neurons into the portal circulation is the primary physiological inhibitor of prolactin secretion. It acts at dopamine type 2 receptors on lactotroph cells to suppress prolactin gene transcription and secretion. A dopamine type 2 receptor antagonist blocks this inhibitory input, allowing prolactin secretion to proceed unchecked. Somatostatin has minimal direct effect on lactotroph prolactin secretion; the other options misstate the receptor location or direction of effect.

Question 9

A man with prostate cancer is started on a depot gonadotropin-releasing hormone agonist. After an initial testosterone rise, his serum testosterone falls to castrate levels within 3 to 4 weeks. Which of the following best explains the sustained testosterone suppression?

A)The agonist directly inhibits testosterone synthesis in Leydig cells by activating inhibitory G proteins
B)Continuous non-pulsatile gonadotropin-releasing hormone receptor occupancy causes receptor downregulation, reducing surface receptor density by 80 to 95% and suppressing luteinizing hormone secretion
C)The depot formulation gradually releases a decreasing amount of drug, shifting from agonist to antagonist activity over several weeks
D)Testosterone exerts direct negative feedback on gonadotropin-releasing hormone receptors in the testes, suppressing its own synthesis

Correct Answer

B) Continuous non-pulsatile gonadotropin-releasing hormone receptor occupancy causes receptor downregulation, reducing surface receptor density by 80 to 95% and suppressing luteinizing hormone secretion

Rationale

Continuous non-pulsatile receptor occupancy by the depot gonadotropin-releasing hormone agonist produces two sequential events: rapid receptor desensitization through protein kinase C-mediated uncoupling from Gq, followed by receptor internalization via a clathrin-independent pathway. Surface receptor density falls by 80 to 95%, eliminating the pituitary Gq signal that drives luteinizing hormone and follicle-stimulating hormone secretion. Without luteinizing hormone stimulation, Leydig cell testosterone synthesis ceases. The drug does not change pharmacodynamic activity over time, and testosterone does not feed back directly on gonadotropin-releasing hormone receptors.

Question 10

Somatostatin analogs suppress growth hormone secretion from pituitary somatotroph cells by activating Gi-coupled somatostatin receptors. Which of the following cellular effects results directly from Gi activation at these receptors?

A)Increased intracellular cyclic adenosine monophosphate via stimulation of adenylyl cyclase
B)Activation of phospholipase C beta generating inositol trisphosphate and diacylglycerol
C)Opening of voltage-gated sodium channels, depolarizing the somatotroph cell membrane
D)Inhibition of voltage-gated calcium channels and opening of inwardly rectifying potassium channels, hyperpolarizing the cell and suppressing exocytosis

Correct Answer

D) Inhibition of voltage-gated calcium channels and opening of inwardly rectifying potassium channels, hyperpolarizing the cell and suppressing exocytosis

Rationale

Gi protein activation produces three coordinated inhibitory effects: inhibition of adenylyl cyclase (reducing cyclic adenosine monophosphate), opening of inwardly rectifying potassium channels (hyperpolarizing the cell), and inhibition of voltage-gated calcium channels (reducing calcium entry required for exocytosis). Together these effects suppress hormone secretion. Gi activation inhibits rather than stimulates adenylyl cyclase. Phospholipase C beta activation is a Gq-mediated event. Voltage-gated sodium channel opening would depolarize, not inhibit, secretion.

Question 11

A woman with schizophrenia treated with risperidone develops amenorrhea and galactorrhea from hyperprolactinemia. Her psychiatrist adds aripiprazole to her regimen without removing risperidone. Which of the following best explains why aripiprazole can normalize prolactin in this setting?

A)Aripiprazole acts as a partial dopamine type 2 receptor agonist at pituitary lactotroph cells, providing sufficient dopaminergic tone to suppress prolactin secretion even in the presence of a full antagonist
B)Aripiprazole blocks prolactin receptors in the breast, preventing galactorrhea without affecting serum prolactin
C)Aripiprazole stimulates somatostatin release from hypothalamic neurons, which then suppresses lactotroph prolactin secretion
D)Aripiprazole competitively displaces risperidone from all dopamine type 2 receptors throughout the brain, restoring normal dopaminergic signaling

Correct Answer

A) Aripiprazole acts as a partial dopamine type 2 receptor agonist at pituitary lactotroph cells, providing sufficient dopaminergic tone to suppress prolactin secretion even in the presence of a full antagonist

Rationale

Aripiprazole is a partial dopamine type 2 receptor agonist with high receptor affinity. At pituitary lactotroph dopamine type 2 receptors, it provides partial agonist activity that is sufficient to restore inhibitory dopaminergic tone and suppress prolactin secretion, even when added to a full antagonist. It does not block prolactin receptors or stimulate somatostatin release. Aripiprazole does not globally displace risperidone; the two drugs coexist at the receptor, but partial agonist activity at the pituitary level is enough to normalize prolactin.

Question 12

Vasopressin receptor 2 is a Gs-coupled G protein-coupled receptor on renal collecting duct cells. Which of the following correctly describes the downstream mechanism by which vasopressin receptor 2 activation produces antidiuresis?

A)Gi activation inhibits adenylyl cyclase, reducing cyclic adenosine monophosphate and allowing aquaporin-2 to remain at the cell surface
B)Gq activation stimulates phospholipase C beta, generating inositol trisphosphate that drives aquaporin-2 vesicle fusion with the apical membrane
C)Gs activation stimulates adenylyl cyclase, raising cyclic adenosine monophosphate and activating protein kinase A, which phosphorylates aquaporin-2 vesicles and drives their insertion into the apical membrane of collecting duct cells
D)Gs activation opens voltage-gated calcium channels, and calcium directly triggers aquaporin-2 exocytosis from intracellular vesicles

Correct Answer

C) Gs activation stimulates adenylyl cyclase, raising cyclic adenosine monophosphate and activating protein kinase A, which phosphorylates aquaporin-2 vesicles and drives their insertion into the apical membrane of collecting duct cells

Rationale

Vasopressin receptor 2 couples to Gs, which stimulates adenylyl cyclase to raise intracellular cyclic adenosine monophosphate. Elevated cyclic adenosine monophosphate activates protein kinase A, which phosphorylates aquaporin-2 water channel proteins stored in intracellular vesicles, triggering their fusion with the apical membrane of collecting duct cells. This increases water permeability and allows water reabsorption from the tubular lumen. Gi signaling inhibits this pathway. Phospholipase C beta activation is a Gq-mediated event. Calcium-triggered exocytosis is not the primary mechanism for aquaporin-2 insertion at this receptor.

Question 13

Native gonadotropin-releasing hormone has a plasma half-life of 2 to 4 minutes. Leuprolide, a synthetic gonadotropin-releasing hormone agonist analog, has a half-life of 3 to 8 hours. Which of the following structural modifications is primarily responsible for this difference in half-life?

A)Substitution of an L-amino acid at position 6, increasing receptor binding affinity
B)Substitution of a D-amino acid at position 6, preventing recognition and cleavage by peptidases at that site
C)Addition of a polyethylene glycol moiety that sterically shields the entire peptide from circulating proteases
D)Replacement of the N-terminal glutamine with a pyroglutamate residue that blocks aminopeptidase access

Correct Answer

B) Substitution of a D-amino acid at position 6, preventing recognition and cleavage by peptidases at that site

Rationale

The primary pharmacokinetic strategy in gonadotropin-releasing hormone analog design is substitution of a D-amino acid at position 6, the principal peptidase cleavage site in the native decapeptide. Peptidases recognize and cleave L-amino acid sequences; D-amino acids at the cleavage site are stereochemically unrecognizable to these enzymes, dramatically slowing degradation and extending half-life from minutes to hours. C-terminal amidation provides additional protection against carboxypeptidase attack. Polyethylene glycol modification is used for other biologic drugs but not gonadotropin-releasing hormone analogs. The N-terminal pyroglutamate structure is present in native gonadotropin-releasing hormone and is not a synthetic modification conferring stability.

Question 14

Corticotropin-releasing hormone stimulates adrenocorticotropic hormone secretion from anterior pituitary corticotroph cells by binding corticotropin-releasing hormone receptor type 1. Which of the following correctly identifies the G protein coupling of this receptor and the second messenger it generates?

A)Gq coupling; generates inositol trisphosphate and diacylglycerol via phospholipase C beta activation
B)Gi coupling; inhibits adenylyl cyclase and lowers intracellular cyclic adenosine monophosphate
C)G12 coupling; activates Rho-kinase and reorganizes the actin cytoskeleton to facilitate exocytosis
D)Gs coupling; stimulates adenylyl cyclase to raise intracellular cyclic adenosine monophosphate, activating protein kinase A and driving pro-opiomelanocortin gene transcription and adrenocorticotropic hormone release

Correct Answer

D) Gs coupling; stimulates adenylyl cyclase to raise intracellular cyclic adenosine monophosphate, activating protein kinase A and driving pro-opiomelanocortin gene transcription and adrenocorticotropic hormone release

Rationale

Corticotropin-releasing hormone receptor type 1 is a Gs-coupled G protein-coupled receptor. Gs activation stimulates adenylyl cyclase, raising intracellular cyclic adenosine monophosphate and activating protein kinase A. Protein kinase A phosphorylates transcription factors that drive pro-opiomelanocortin gene transcription and promotes exocytosis of adrenocorticotropic hormone-containing secretory granules. Gq coupling produces inositol trisphosphate and diacylglycerol via phospholipase C beta; this is the pathway used by the gonadotropin-releasing hormone receptor and thyrotropin-releasing hormone receptor, not by corticotropin-releasing hormone receptor type 1. Gi coupling inhibits rather than stimulates adenylyl cyclase.

Clinical Correlations · Questions 15–18

Apply pharmacological knowledge to clinical scenarios. Each vignette presents a patient situation; the question tests mechanism of action or drug selection.

Question 15

A 68-year-old man with metastatic prostate cancer and known vertebral metastases receives his first intramuscular injection of leuprolide depot. Over the following week, he develops worsening back pain. Serum testosterone measured on day 7 is 680 ng/dL, well above his pretreatment level of 420 ng/dL. Which of the following best explains the testosterone elevation during this initial period?

A)The depot formulation releases an initial large bolus of drug that directly stimulates Leydig cell testosterone synthesis through a gonadotropin-independent pathway
B)The gonadotropin-releasing hormone agonist competitively displaces endogenous gonadotropin-releasing hormone from its receptor, producing a rebound surge of luteinizing hormone that peaks at 7 days
C)The gonadotropin-releasing hormone agonist activates the gonadotropin-releasing hormone receptor through the same Gq-mediated pathway as endogenous gonadotropin-releasing hormone, producing an initial surge of luteinizing hormone and follicle-stimulating hormone before receptor downregulation suppresses gonadotropin secretion
D)Testosterone elevation at day 7 reflects renal clearance delay of endogenous testosterone that accumulated during the prodromal period before therapy

Correct Answer

C) The gonadotropin-releasing hormone agonist activates the gonadotropin-releasing hormone receptor through the same Gq-mediated pathway as endogenous gonadotropin-releasing hormone, producing an initial surge of luteinizing hormone and follicle-stimulating hormone before receptor downregulation suppresses gonadotropin secretion

Rationale

Gonadotropin-releasing hormone agonist analogs bind and activate the gonadotropin-releasing hormone receptor through the same Gq-coupled signaling cascade as endogenous gonadotropin-releasing hormone: phospholipase C beta activation, inositol trisphosphate and diacylglycerol generation, calcium mobilization, and protein kinase C activation drive an initial surge of luteinizing hormone and follicle-stimulating hormone secretion. In men with prostate cancer, serum testosterone rises 50 to 80% above baseline during this flare period, which can exacerbate symptoms in patients with vertebral metastases. Receptor downregulation and the transition to testosterone suppression occur over the subsequent 3 to 4 weeks. The mechanism is initial receptor activation, not blockade or pharmacokinetic delay.

Question 16

A 29-year-old woman with schizophrenia has been taking risperidone for 4 months. She now reports milky nipple discharge and her last three menstrual periods have been absent. Serum prolactin is 94 ng/mL (normal less than 25 ng/mL). Which of the following best explains the mechanism of her hyperprolactinemia?

A)Risperidone stimulates dopamine type 2 receptors on tuberoinfundibular dopaminergic neurons, increasing dopamine release into the portal circulation and paradoxically elevating prolactin through a presynaptic mechanism
B)Risperidone blocks dopamine type 2 receptors on pituitary lactotroph cells, preventing dopamine from exerting its tonic inhibitory effect on prolactin secretion
C)Risperidone inhibits somatostatin release from hypothalamic neurons, removing an inhibitory signal that normally suppresses prolactin gene transcription
D)Risperidone activates estrogen receptors on lactotroph cells, mimicking the prolactin-stimulating effect of estrogen at the pituitary level

Correct Answer

B) Risperidone blocks dopamine type 2 receptors on pituitary lactotroph cells, preventing dopamine from exerting its tonic inhibitory effect on prolactin secretion

Rationale

Dopamine released from tuberoinfundibular dopaminergic neurons into the hypothalamic-pituitary portal circulation acts at dopamine type 2 receptors on anterior pituitary lactotroph cells to tonically suppress prolactin secretion. Risperidone, a potent dopamine type 2 receptor antagonist, blocks these pituitary receptors, removing this inhibitory signal and allowing prolactin secretion to increase substantially. The result is hyperprolactinemia manifesting as galactorrhea and suppression of the hypothalamic-pituitary-gonadal axis, causing amenorrhea. Risperidone does not stimulate presynaptic dopamine release, affect somatostatin signaling, or interact with estrogen receptors.

Question 17

A 45-year-old woman with acromegaly is started on octreotide long-acting release after inadequate growth hormone control with surgery. Two months later, her fasting blood glucose has risen from 98 mg/dL to 162 mg/dL. Her growth hormone and insulin-like growth factor-1 levels have improved significantly. Which of the following best explains the mechanism of her elevated blood glucose?

A)Octreotide activates somatostatin receptors on pancreatic beta cells, and the resulting Gi-mediated suppression of cyclic adenosine monophosphate reduces insulin secretion
B)Octreotide stimulates glucagon secretion from pancreatic alpha cells by activating Gs-coupled somatostatin receptors, raising hepatic glucose production
C)Octreotide blocks insulin receptors on skeletal muscle cells, reducing glucose uptake despite normal circulating insulin levels
D)Octreotide reduces growth hormone levels, eliminating the insulin-sensitizing effect of growth hormone that had been maintaining normal glucose tolerance

Correct Answer

A) Octreotide activates somatostatin receptors on pancreatic beta cells, and the resulting Gi-mediated suppression of cyclic adenosine monophosphate reduces insulin secretion

Rationale

Octreotide is a somatostatin receptor subtype 2 and subtype 5-selective analog. Somatostatin receptors are Gi-coupled G protein-coupled receptors. In pancreatic beta cells, Gi activation inhibits adenylyl cyclase, lowers intracellular cyclic adenosine monophosphate, opens inwardly rectifying potassium channels, and inhibits voltage-gated calcium channels, together suppressing insulin exocytosis. Reduced insulin secretion impairs glucose uptake and raises blood glucose. Somatostatin receptors on glucagon-secreting alpha cells are also inhibited by octreotide, which would lower rather than raise glucagon. Growth hormone is diabetogenic, not insulin-sensitizing, so its reduction by octreotide would tend to improve rather than worsen glucose tolerance.

Question 18

A 54-year-old man with hypertension and stable angina has been taking verapamil for 8 months. He reports new-onset breast tenderness and milky nipple discharge. Serum prolactin is 58 ng/mL. He takes no other medications. Which of the following best explains the mechanism of his hyperprolactinemia?

A)Verapamil blocks dopamine type 2 receptors on pituitary lactotroph cells, preventing tonic inhibition of prolactin secretion
B)Verapamil stimulates thyrotropin-releasing hormone release from the hypothalamus, which then directly stimulates lactotroph prolactin secretion
C)Verapamil inhibits somatostatin secretion from the arcuate nucleus, removing inhibitory tone on prolactin gene transcription
D)Verapamil interferes with calcium-dependent dopamine release from tuberoinfundibular dopaminergic nerve terminals, reducing portal dopamine delivery to the pituitary and disinhibiting prolactin secretion

Correct Answer

D) Verapamil interferes with calcium-dependent dopamine release from tuberoinfundibular dopaminergic nerve terminals, reducing portal dopamine delivery to the pituitary and disinhibiting prolactin secretion

Rationale

Verapamil is a voltage-gated calcium channel blocker. Calcium entry through voltage-gated calcium channels at the nerve terminals of tuberoinfundibular dopaminergic neurons is required for dopamine exocytosis into the hypothalamic-pituitary portal circulation. Verapamil blocks these channels in dopaminergic nerve terminals, impairing calcium-dependent dopamine release. With less dopamine delivered to pituitary lactotroph dopamine type 2 receptors, the tonic inhibition of prolactin secretion is reduced and prolactin rises. Verapamil does not directly block dopamine type 2 receptors at the pituitary, stimulate thyrotropin-releasing hormone, or affect somatostatin secretion.